HighTower Advisors
EDIT icon

HighTower Advisors’s Editas Medicine EDIT Stock Holding History

HighTower Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,500
Closed -$825 – 3713
2023
Q4 		$825 Buy
+1,500
New +$13.2K ﹤0.01% 3551
2023
Q3 		– Sell
-20
Closed -$700 – 3614
2023
Q2 		$700 Buy
+20
New +$174 ﹤0.01% 3394

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HighTower Advisors's EDIT Position: Q2 2026 in Review

HighTower Advisors increased its Editas Medicine (EDIT) stake by 8.5% in Q2 2026, buying an estimated $4.94K and bringing the position to 21,518 shares worth $69.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3695.

HighTower Advisors first reported a position in EDIT in Q3 2018 and has held it in 27 quarters since. The position peaked at $3.31M in Q2 2021. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • HighTower Advisors held 21,518 shares of Editas Medicine worth $69.7K as of Q2 2026.
  • HighTower Advisors bought 1,690 Editas Medicine shares in Q2 2026, an estimated $4.94K.
  • Editas Medicine made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3695 holding.
  • HighTower Advisors first reported a position in Editas Medicine in Q3 2018 and has held it in 27 quarters since.
  • HighTower Advisors's Editas Medicine position peaked at $3.31M in Q2 2021.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.